Proactive Investors - Run By Investors For Investors

FDA accepted CytoDyn’s request and plan to submit BLA on rolling basis

CytoDyn Inc. (OTCQB:CYDY) President and CEO Dr. Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to talk about encouraging news that the FDA will allow CytoDyn to submit on a rolling basis its planned Biologics License Application for  Leronlimab. This is a humanized IgG4 mAb that is subcutaneously injected to block HIV-1 from entering and infecting immune cells.

Pourhassan told Proactive how rare this is for a company their size and when the first submissions will be made. 

 
View full CYDY profile View Profile

CytoDyn Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use